2C-B: Effects, Dosage & Harm Reduction

What 2C-B Is

2C-B was first synthesised by American chemist Alexander Shulgin in 1974 and published in his 1991 compendium PiHKAL: A Chemical Love Story, which documented hundreds of phenethylamine compounds alongside Shulgin's careful self-experimentation notes. After a brief period of legal sale in the United States as a short-lived alternative to MDMA, 2C-B was placed in Schedule I in 1995. It is a Schedule III substance in Canada.

2C-B belongs to the 2C-x family of psychedelic phenethylamines — compounds derived from 2,5-dimethoxyphenethylamine with various substitutions at the 4-position. The bromine substitution gives 2C-B its specific character. The "2C" family also includes 2C-I, 2C-E, 2C-P, and others — all with different potencies, durations, and risk profiles.

Pharmacology

Like classical psychedelics, 2C-B acts as a 5-HT2A receptor agonist. It also has significant activity at other serotonin receptor subtypes and some dopaminergic activity, producing a phenomenological character that many describe as combining qualities of psilocybin's warmth with MDMA's entactogenic sensibility — more visually elaborated than MDMA, more embodied and sensory than LSD.

The phenethylamine structure means 2C-B is metabolised differently from tryptamine psychedelics. It is not a substrate for MAO in the same way as DMT, meaning MAOIs do not dramatically potentiate it in the way they do ayahuasca. However, serotonergic interactions and combination risks still apply.

Effects

Onset (45–75 minutes)

Relatively slow onset — which has led to redosing accidents when users assume the first dose is not working. The onset is gradual and typically pleasant: a gentle warmth and perceptual brightening, mild tingling.

Peak (2–4 hours)

2C-B is characterised by strong visual effects even at moderate doses — colour enhancement, patterns, and figurative imagery are prominent. The emotional quality is often described as warm, sensory, and grounded rather than the emotionally confrontational intensity of psilocybin at equivalent experiential depth. Music, touch, and embodied sensation are typically heightened. The experience is often described as more navigable and less psychologically destabilising than psilocybin or LSD at comparable doses.

Duration

4–6 hours total — comparable to psilocybin, notably shorter than LSD. This is one of 2C-B's practical advantages: the experience is briefer and the return to baseline is typically clean, without LSD's long tail.

Dosage: The Most Critical Consideration

2C-B has one of the steepest dose-response curves of any psychedelic. The difference between 15 mg, 25 mg, and 35 mg is not a gradual progression — it is qualitatively distinct territory. This is the most important harm reduction consideration for 2C-B.

2C-B vs. Psilocybin and LSD

Duration. 2C-B (4–6 hours) is comparable to psilocybin and substantially shorter than LSD — a practical advantage for many users.

Visual character. 2C-B's visuals are typically more elaborated and more stable than psilocybin at equivalent doses — geometric, colourful, and detailed. LSD visuals tend to be crisper and more motion-based.

Emotional character. 2C-B is generally less emotionally confrontational than psilocybin. It tends not to produce the profound ego dissolution or the deeply psychological material that psilocybin frequently surfaces — which practitioners describe both as a limitation (for deep therapeutic work) and as an advantage (for people new to psychedelics or seeking a more navigable experience).

Ecological phenomenology. 2C-B produces ecological and relational themes less consistently than psilocybin or ayahuasca in the available literature. Its more sensory and visual character may support embodied presence without the profound relational insights characteristic of tryptamine psychedelics.

Tolerance. Rapid tolerance develops within days; cross-tolerance with psilocybin and LSD is substantial.

Risks and Contraindications

2C-B shares standard psychological contraindications with all classical psychedelics: personal or family history of schizophrenia spectrum disorders or bipolar I. Cardiovascular: moderate increase in heart rate and blood pressure. The same drug interaction considerations apply — particularly with SSRIs, MAOIs, and lithium.

Redosing risk. 2C-B's slow onset frequently prompts impatient redosing before the first dose has taken effect. A dose taken at 45 minutes that seems to have done nothing will often arrive in full force at 60–90 minutes — combined with the redose, this can produce an unexpectedly intense experience. Wait a minimum of 90 minutes before concluding that a dose has not worked.

Adulteration. 2C-B is sometimes sold as MDMA or mixed with other substances. Testing is essential.

Testing 2C-B

The Marquis reagent turns yellow-green for 2C-B (distinct from MDMA's purple/black). The Mecke reagent turns blue-green. The Froehde reagent turns orange-brown. Using multiple reagents provides better confidence than any single test. Fentanyl test strips should always be used as an additional check.

Frequently Asked Questions